| In Vivo Biology |
|
| The In Vivo Biology department at Jubilant has state of the art infrastructure and the expertise to conduct PK-PD and efficacy studies in various disease models related to oncology, metabolic disorder, pain, inflammation and respiratory disease therapeutic areas. |
|
| Our state-of- the art animal facility houses nude mice, rodents and rabbits for immune-compromised strains. Animal studies are conducted under the guidance of Institutional Ethics Committee and are overseen by experts in each of the models and disease areas. |
|
|
|
| Pain models and biomarkers |
| NOCICEPTIVE PAIN |
- Formalin Induced Paw Licking and Biting in Rats
- Acetic Acid Writhing Test in Mice
- Hot Plate model
- Tail flick model
|
|
| INFLAMMATORY PAIN |
- Carrageenan induced inflammation (Paw volume, Paw Thickness , Thermal Hyperalgesia in rats
- CFA induced Thermal Hyperalgesia/mechanical hyperalgesia/allodynia in rats
- Collagen-induced Arthritis (CIA) in DBA mice
|
|
|
| NEUROPATHIC PAIN MODELS |
- CCI-induced Neuropathic Pain in Rats (Bennet & Xie model)
- L5/L6 ligation-induced neuropathic (Chung’s model)
- Streptozotocin (STZ)-induced Diabetic Neuropathy in Rats
- Chemotherapy (Paclitaxel) induced neuropathic pain
|
| BIOMARKER ANALYSIS |
- INF-γ measurement from plasma and media
- IL1-β from culture media
- TNF-α from plasma and media
|
|
| TARGET ENGAGEMENT |
- Coupled with biomarker analysis for in vitro- in vivo correlation and Human dose projection
|
|
|
| Top |
|
| Oncology models and biomarkers |
| Sucutaneous Xenograft models |
- Lung (NCI-H82, HCC827, Calu-6)
- Breast (MDA-MB-231)
- Colon (HT-29, Colo-205, HCT116)
- Prostate (PC3, DU-145, LNCaP)
- Gastric (MKN-45)
- Pancreatic (PANC-1)
- Others (A431, U-87 MG, B16-F10)
|
|
| Orthotopic Xenograft models |
|
|
|
| Metastatic Xenograft models |
|
|
|
|
| Syngeneic tumor models |
|
|
|
| Matrigel plug angiogenesis model |
|
| PK-PD models |
- Xenograft tumors
- Western blot, ELISA, MSD and FACS based PD marker assessment in tumor tissue
- Correlation of PK, PD and efficacy
- Projection of therapeutic index and efficacious human dose
|
|
|
| Top |
|
| Metabolic Disorder models and biomarkers |
| Screening Models in Mice and Rats |
- OGTT, IPGTT
- Diet Induced obesity (DIO)
- OLTT
- Incretin and endocrine secretion - GLP-1, PYY/CCK
|
|
| Models under development |
- Hyperinsulinemic Clamp
- Fatty Acid Oxidation
- In Vivo Adipolysis
- Hypercholesterlemia / Dyslipidemia
|
|
|
| Biomarker Analysis |
- Apo B, Insulin, GLP-1, glucagon, adiponectin, triglyceride & cholesterol
- Gene expression analysis in cells & ex vivo tissues
|
|
| Dydlipidemia and Hyperglycemia Models |
- db/db & ab/ab
- Streptozotocin induced diabetes
- ZDF & Zucker fa/fa
|
|
|
| Top |
|
|
|
